FDA warning letter tracker for peptide sellers
Each row is an FDA warning letter whose text names a peptide product or a research use only peptide sale. The recipient, the letter date and a link to the letter on fda.gov are shown. This tracker is not complete and is not legal advice.
| Recipient | Letter date | Products or practices named | Source and retrieved date |
|---|---|---|---|
| NuScience Peptides LLC | August 24, 2026 | Website offering products labeled research peptides, including retatrutide, survodutide and tesamorelin, cited by FDA as unapproved new drugs. | Source: fda.gov letter Retrieved October 7, 2026 |
| Peak Performance Peptides | August 24, 2026 | Website offering retatrutide, semaglutide, SS-31, PT-141 and tesamorelin, cited by FDA as unapproved new drugs. | Source: fda.gov letter Retrieved October 7, 2026 |
| Peptide Partners LLC | August 24, 2026 | Website offering semaglutide, tirzepatide, retatrutide, SS-31, tesamorelin and PT-141 peptide products, cited by FDA as unapproved new drugs. | Source: fda.gov letter Retrieved October 7, 2026 |
| Royal Peptides LLC | August 24, 2026 | Website offering tirzepatide, semaglutide, retatrutide, SS-31, PT-141, tesamorelin and Bimorelin, cited by FDA as unapproved new drugs. | Source: fda.gov letter Retrieved October 7, 2026 |
| TXP Innovations LLC dba Tex Peptides | August 24, 2026 | Website offering semaglutide, tirzepatide, retatrutide, SS-31, tesamorelin and PT-141 peptide products, cited by FDA as unapproved new drugs. | Source: fda.gov letter Retrieved October 7, 2026 |
| Wholesale Peptide | June 17, 2026 | Website offering Prostamax and gonadorelin peptide products, cited by FDA as unapproved new drugs. | Source: fda.gov letter Retrieved October 7, 2026 |
| Gram Peptides | March 31, 2026 | Website offering retatrutide and tirzepatide sold as peptide products with research use only labeling, cited by FDA as unapproved new drugs. | Source: fda.gov letter Retrieved October 7, 2026 |
| Lovega LLC dba Pink Pony Peptides | March 31, 2026 | Website offering peptide products named GLP-2 TZ and GLP-3 RT, cited by FDA as unapproved new drugs. | Source: fda.gov letter Retrieved October 7, 2026 |
| Mile High Compounds LLC | March 31, 2026 | Website and linked community forum offering peptide products named GLP-1 SM, GLP-2 TRZ and GLP-3 RT, cited by FDA as unapproved new drugs. | Source: fda.gov letter Retrieved October 7, 2026 |
| Prime Sciences | March 31, 2026 | Website offering cagrilintide, mazdutide and GLP1 named products described as research peptides, cited by FDA as unapproved new drugs. | Source: fda.gov letter Retrieved October 7, 2026 |
| Darmerica, LLC | December 8, 2025 | Distribution of peptide active pharmaceutical ingredients to compounders, including GLP-1 APIs shipped as custom peptide with the drug name omitted, cited by FDA for violations of the FD&C Act. | Source: fda.gov letter Retrieved October 7, 2026 |